Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
J Infect Dis
; 215(12): 1807-1815, 2017 06 15.
Article
in En
| MEDLINE
| ID: mdl-28472421
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Virus Replication
/
Coronavirus Infections
/
Dipeptidyl Peptidase 4
/
Antibodies, Neutralizing
/
Middle East Respiratory Syndrome Coronavirus
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
Limits:
Animals
/
Humans
/
Male
Language:
En
Journal:
J Infect Dis
Year:
2017
Document type:
Article